PDCD1 and neoplasm: Notably, anti-PD-1 monotherapy favored Cd24+ cells (Fig. 6k), which underwent a metabolic shift from oxidative phosphorylation to glycolysis (Supplementary Fig. S7a, b and Supplementary Table 10), highlighting their metabolic adaptability.19 Gene expression analysis showed enhanced immune receptor signaling in tumor cells from BT- or combination-treated mice, whereas control and anti-PD-1 monotherapy groups were enriched in RNA metabolism, translation, and cell cycle-related pathways (Supplementary Fig. S7b).